Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial

• Published in: The Lancet infectious diseases 2018-10, Vol.18 (10), p.1097-1107
• Main Authors: Divala, Titus H, Mungwira, Randy G, Mawindo, Patricia M, Nyirenda, Osward M, Kanjala, Maxwell, Ndaferankhande, Masiye, Tsirizani, Lufina E, Masonga, Rhoda, Muwalo, Francis, Boudová, Sarah, Potter, Gail E, Kennedy, Jessie, Goswami, Jaya, Wylie, Blair J, Muehlenbachs, Atis, Ndovie, Lughano, Mvula, Priscilla, Mbilizi, Yamikani, Tomoka, Tamiwe, Laufer, Miriam K
• Format: Article
• Language: English
• Subjects: Adult; Age; Analysis; Anemia; Antimalarial agents; Antimalarials - therapeutic use; Babies; Birth weight; Chloroquine; Chloroquine - adverse effects; Chloroquine - therapeutic use; Clinical trials; Control; Drug Combinations; Drug dosages; Drug therapy; Effectiveness; Female; Gestation; Gestational age; Hemoglobin; High resistance; Histochemistry; Histopathology; HIV; Human immunodeficiency virus; Humans; Infant, Newborn; Infections; Infectious diseases; Malaria; Malaria - prevention & control; Medicine, Preventive; Obstetrics; Placenta; Pregnancy; Pregnancy Complications, Parasitic - prevention & control; Pregnant women; Prevention; Preventive health services; Prophylaxis; Pyrimethamine; Pyrimethamine - adverse effects; Pyrimethamine - therapeutic use; Randomization; Sulfadoxine; Sulfadoxine - adverse effects; Sulfadoxine - therapeutic use; Therapy; Vector-borne diseases; Womens health
• ISSN: 1473-3099; 1474-4457
• DOI: 10.1016/S1473-3099(18)30415-8

Sulfadoxine-pyrimethamine resistance threatens efficacy of intermittent preventive treatment of malaria during pregnancy, and alternative regimens need to be identified. With the return of chloroquine efficacy in southern Africa, we postulated that chloroquine either as an intermittent therapy or as weekly chemoprophylaxis would be more efficacious than intermittent sulfadoxine-pyrimethamine for prevention of malaria in pregnancy and associated maternal and newborn adverse outcomes. We did an open-label, single-centre, randomised controlled trial at Ndirande Health Centre, Blantyre, in southern Malawi. We enrolled pregnant women (first or second pregnancy) at 20–28 weeks' gestation who were HIV negative. Participants were randomly assigned in a 1:1:1 ratio using a computer-generated list to either intermittent sulfadoxine-pyrimethamine (two doses of 1500 mg sulfadoxine and 75 mg pyrimethamine, 4 weeks apart), intermittent chloroquine (two doses of 600 mg on day 1, 600 mg on day 2, and 300 mg on day 3), or chloroquine prophylaxis (600 mg on day 1 then 300 mg every week). The primary endpoint was placental malaria in the modified intent-to-treat population, which consisted of participants who contributed placental histopathology data at birth. Secondary outcomes included clinical malaria, maternal anaemia, low birthweight, and safety. This trial is registered with ClinicalTrials.gov, number NCT01443130. Between February, 2012, and May, 2014, we enrolled and randomly allocated 900 women, of whom 765 contributed histopathological data and were included in the primary analysis. 108 (14%) women had placental malaria, which was lower than the anticipated prevalence of placental malaria infection. Protection from placental malaria was not improved by chloroquine as either prophylaxis (30 [12%] of 259 had positive histopathology; relative risk [RR] 0·75, 95% CI 0·48–1·17) or intermittent therapy (39 [15%] of 253; RR 1·00, 0·67–1·50) compared with intermittent sulfadoxine-pyrimethamine (39 [15%] of 253). In protocol-specified analyses adjusted for maternal age, gestational age at enrolment, bednet use the night before enrolment, anaemia at enrolment, and malaria infection at enrolment, women taking chloroquine as prophylaxis had 34% lower placental infections than did those allocated intermittent sulfadoxine-pyrimethamine (RR 0·66, 95% CI 0·46–0·95). Clinical malaria was reported in nine women assigned intermittent sulfadoxine-pyrimethamine, four allocated intermitt